Browse site A – Z

Your views

Your Views

Your feedback is vital to us as we continue to increase the quality of our services.

Your views

You are here:

Date: 27 September 2023

Time: 22:33

Image: CyberKnife treatment in action

CyberKnife treatment

At the Queen Elizabeth Hospital Birmingham (QEHB), we offer a fully accredited CyberKnife treatment service for NHS and private patients.

Cyberknife at QEHB is commissioned by the NHS to treat:

Intracranial (within the brain)

  • Brain metastases (secondary cancer deposits from a cancer elsewhere in the body)
  • Acoustic neuromas
  • Meningiomas

Less commonly:

  • Pituitary tumours
  • Glomus tumours

Extracranial (outside the brain)

  • Lung cancer


In certain clinical situations we are able to treat:

  • Prostate patients - privately and via the PACE trial
  • Isolated solitary metastases are now eligible to be considered for treatment under NHS England's Commissioning through Evaluation (CtE) programme. The eligibility criteria are:
    • Metastatic carcinoma with either a histologically or cytologically proven primary site or a male patient with a PSA>50 and clinical evidence of prostate cancer
    • 1-3 sites of metastatic disease (defined after appropriate imaging) which can be treated with stereotactic radiotherapy to a radical radiation dose.
    • A maximum of two sites of spinal metastatic disease
    • Maximum size of any single metastasis 6cm (5 cm for lung or liver metastases)
    • Disease free interval > 6 months; unless synchronous liver metastases from colorectal primary (see liver metastases section)
    • Not more than three oligometastatic sites treated in total per patient
    • Expected life expectancy > 6 months
    • Performance status ≤ 2
    • All patients to be discussed at stereotactic MDT with presence of, or prior discussion with a disease site specific oncologist
    • All patients willing to attend follow up and have details collected on prospective database for a minimum of two years


We're improving the accessibility of our websites. If you can't access any content or if you would like to request information in another format, please view our accessibility statement.